^
Association details:
| Biomarker: | MDM2 amplification + TP53 wild-type + TWIST1 amplification |
|---|---|
| Cancer: | Sarcoma |
| Drug: | milademetan (RAIN-32) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Published date:
08/04/2023
Excerpt:
We conducted a phase Ib/II study in patients with MDM2-amplified, wild-type TP53 intimal sarcoma as a substudy of a large nationwide registry for rare cancers in Japan. Milademetan (260 mg) was administered orally once daily for 3 days every 14 days, twice in a 28-day cycle....Antitumor activity correlated with TWIST1 amplification (P = 0.028)...
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0419
